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Abstract
Background and objectives
Chronic kidney disease (CKD) is a global health burden and is independently associated
with increased cardiovascular disease risk. Assessment of cardiovascular risk in the general
population using prognostic models based on routinely collected risk factors is embedded in
clinical practice. In CKD, prognostic models may misrepresent risk due to the interplay of
traditional atherosclerotic and non-traditional risk factors. This systematic review’s aim was
to identify routinely collected risk factors for inclusion in a CKD-specific cardiovascular prog-
nostic model.
Design, setting, participants and measurements
Systematic review and meta-analysis of observational cohort studies and randomized con-
trolled trials. Studies identified from MEDLINE and Embase searches using a pre-defined
and registered protocol (PROSPERO ID—2016:CRD42016036187). The main inclusion
criteria were individuals18 years of age with non-endstage CKD. Routinely collected risk
factors where multi-variable adjustment for established cardiovascular risk factors had
occurred were extracted. The primary outcome was fatal and non-fatal cardiovascular
events.
Results
The review of 3,232, abstracts identified 29 routinely collected risk factors of which 20 were
presented in more than 1 cohort. 21 cohorts were identified in relation to 27,465 individuals
and 100,838 person-years. In addition to established traditional general population cardio-
vascular risk factors, left ventricular hypertrophy, serum albumin, phosphate, urate and
hemoglobin were all found to be statistically significant in their association with future cardio-
vascular events.
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Conclusions
These non-traditional risk factors should be assessed in the development of future cardio-
vascular prognostic models for use in individuals with CKD.
Introduction
Chronic kidney disease (CKD) is a global health burden estimated to affect up to 15% of adult
populations [1–3] and is independently associated with increased cardiovascular (CV) disease
risk similar to the risk of diabetes mellitus or coronary heart disease [1–2]. This risk increases
as CKD advances and is evidenced by worsening excretory function, usually manifest as
declining glomerular filtration rate, and increasing proteinuria [3–4]. The overall cost of CKD
accounts for 1.3% of healthcare budgets [5] of which 13% is related to the excess myocardial
infarctions and strokes associated with CKD [5].
Assessment of CV risk using prognostic models in the general population, particularly for
primary prevention, is embedded in clinical practice [6–9]. Such prognostic models use data
from routinely collected risk factors and can be automated using electronic medical records
into routine clinical care. CV prognostic models developed specifically for CKD have signifi-
cant methodological weaknesses, including no external validation and limited model metrics’
assessment, and thus may miscalculate risk in CKD. This contributes to their lack of clinical
utility [10].
To our knowledge no systematic review has been performed to identify routinely collected
risk factors that may potentially contribute to a composite CV outcome prognostic model in
CKD. A new risk factor is only clinically useful if it adds predictive performance to a model
beyond currently utilized standard risk factors, i.e. once a model has been adjusted for said fac-
tors, therefore additional risk factors must be novel and routinely collected in clinical care.
Therefore, assessment of these factors is crucial before prognostic models can be rationally
optimised.
Specific validation in CKD is warranted because the relative role of atherosclerosis in CV
outcomes diminishes, and is replaced by the confounding—‘non-traditional’ CV risk factors.
These uremia-related risk factors may have an increasingly important role with advancing
CKD [11]. This may warrant inclusion of risk factors such as calcium and phosphate [12],
related to arteriosclerosis and reduced vascular compliance, in CKD-specific CV prognostic
models. Equally, consideration of risk factors associated with cardiomyopathy, such as echo-
cardiographic evidence of left ventricular dysfunction or systemic inflammation may also be
justified [11]. Thus other novel routinely collected risk factors require consideration for valida-
tion of CV prognostic models in CKD.
The aim of this systematic review was to identify routinely collected risk factors with poten-
tial value in CV risk prediction in CKD beyond those already included in existing CV prognos-
tic models to inform the development of future CKD-specific CV prognostic models.
Methods
Ovid MEDLINE and Embase were searched using a pre-defined and registered systematic
review and meta-analysis protocol [13] (PROSPERO ID—2016:CRD42016036187). Search
strategies are available in the Supporting Information (Tables A and B in S1 File). Reporting of
the current systematic review follows the PRISMA guidance, also available in the Supporting
Cardiovascular disease risk factors and CKD
PLOS ONE | https://doi.org/10.1371/journal.pone.0192895 March 21, 2018 2 / 18
Information (S2 File). The inclusion criteria were observational cohort studies and secondary
analyses of randomized controlled trials in adult (18 years of age) with either CKD stage 3a
or worse (any eGFR formula <60 ml/min/1.73m2) or proteinuria based on standard defini-
tions [14]. The search was limited to English language manuscripts. General population studies
with subgroup analysis presenting results for CKD groups were also included. Studies includ-
ing individuals with end-stage renal disease, either receiving maintenance dialysis or with a
renal transplant, were excluded. Studies of outcomes after acute kidney injury were also
excluded. The minimum follow-period was six months. A formal definition of CKD using a
standardised eGFR formula was first established in 1999 [15], therefore the search range was
restricted from this date until 20th October 2017.
The primary outcome was a composite of CV disease events which includes acute coronary
syndrome (including unstable angina), congestive cardiac failure and ischemic stroke. Com-
posite CV outcomes including CV-specific mortality were included unless CV events were
grouped with all-cause mortality and/or renal related outcomes.
For the purposes of this paper ‘risk factor’ will be used throughout to mean a measurable
variable at the start of a study that is associated with a future CV disease event during the
study’s follow-up. Any variable was considered as a candidate risk factor if it was collected at
or prior to the start point of the observational period for the study. In addition, factors were
only included if they were likely to be routinely collected as part of standard primary care
clinical practice. Whether a variable was routinely collected was assessed independently by
three clinicians (RM, IO, GX). Where there was disagreement regarding a variable’s inclu-
sion, it was discussed between the three assessors until a consensus was reached. For all
other stages of the methods, assessment was performed independently by at least two of
the authors. Where discrepancies occurred, results were compared until a consensus was
reached. If no consensus was achievable, a further author was consulted to make a final
decision.
The title and abstracts of all studies identified by the literature search were assessed.
The full text of any abstract meeting the inclusion criteria was then reviewed. Data were
extracted using a standardised extraction form which included a risk of bias assessments
based on the ‘Quality in Prognostic Studies’ tool [16]. Confounders adjusted for in each
model were also extracted. The data extraction form was modified and optimised after
data collection from three manuscripts had been performed. High risk of bias was not used
as a reason for excluding a study. Where missing data in relation to a cohort’s characteristics
or model were not published, the corresponding author for the cohort was contacted via
email.
Data for the risk factors were extracted in the form of hazard ratios (HR) and 95% confi-
dence intervals (CI) for the primary outcome. Categorical risk factors were standardised to the
same reference category and continuous variables to the same units (Table C in S1 File). For
example, the gender risk factor was presented as the risk for being male. Where different units
were reported for the same variable, those units reported in the majority of studies were used,
and the minority studies’ results were converted to the same units. A random effects model
using the Mantel-Haenszel method was used as heterogeneity was expected to be present [17].
Data were meta-analysed where more than one study reported results for the same risk factor.
Heterogeneity was assessed using the I2 statistics. Subgroup analysis was considered by CKD
stage including both eGFR and proteinuria. Due to the limited clinical applicability and bias of
univariate analysis of risk factors, only results from studies where multi-variate adjustment for
traditional CV risk factors were considered further. Models were then assessed for the number
of ‘core’ risk factors they adjusted for. Core risk factors included age, gender, ethnicity, body
mass index, smoking, diabetes mellitus, hypertension, CV disease and dyslipidemia. These risk
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factors are all included in general population prognostic tools or have a firmly established asso-
ciation with CV disease risk [2,6,7,18]. In addition, because of their additive benefit to CV
prognostic tools [4], eGFR and proteinuria measurements were also included as core adjust-
ment co-variates. Where the same study had published results for a risk factor in more than
one manuscript the paper with the most complete data was used. If the data were the same,
the results from the most recent publication were used. Where more than one model was
presented in the same publication, the model with the greatest number of core risk factors
included was used. All statistical analysis was performed using Stata version 14.1.
Results
Three thousand two hundred and thirty-two abstracts were reviewed. Fig 1 shows the screen-
ing process, including the number of cohorts and risk factors identified, and reasons for any
Fig 1. Flowchart showing the number of cohorts and risk factors identified, screened and included in the systematic review.
https://doi.org/10.1371/journal.pone.0192895.g001
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exclusion. Twenty-one cohorts were included in the systematic review [19–39]. Fourteen
(66.7%) studies were observational cohort studies with recruitment from nephrology outpa-
tient settings and the others were randomized controlled trials. Six cohorts provided additional
data [19–24].
Overall a total of 27,465 individuals were included in these studies representing a cumu-
lative total of 100,838 person-years. Table 1 summarises the characteristics of the cohorts
contributing to the systematic review. The risk of bias for all studies was medium to high
(see Table D in S1 File). In addition to the observational nature of the studies as a source of
bias, other factors relating to study participant inclusion and exclusion, assessment of out-
comes, reporting of missing data and statistical methods were considered. Six cohorts
(28.6%) were recruited from a single-center. CV outcomes were broadly similar but 15 stud-
ies (71.4%) did not blind their outcome assessors. Seven cohorts (33.3%) reported no infor-
mation in relation to missing data. No study pre-specified or registered their published
analysis plan.
Sixty-six potential risk factors for CV events were identified (Table E in S1 File). Twenty-
nine of these were deemed to be routinely collected and were therefore included in the sys-
tematic review. Nine risk factors were only reported in one study and therefore the data on
20 risk factors reported in multiple studies were pooled to produce a single estimate. The
confounders which were adjusted for in all the included models are shown in Table 2. Age
was corrected for in 20 out of 21 models (95.2%) and was the most frequently adjusted for
variable. Diabetes mellitus was corrected for in 17 out of 19 models (89.5%) making it the co-
morbidity most frequently corrected for. Ethnicity was included in four models, five models
had no published ethnicity data and eleven cohorts had a population with a single ethnicity
making up more than 90% of the population. Seventeen (81.0%) studies corrected for eGFR
and eleven (52.4%) for proteinuria. Three studies (14.3%) adjusted for all established core
CV risk factors.
Data for the extracted risk factors are shown in Table 3. The forest plots for the non-tradi-
tional risk factors of albumin, haemoglobin, phosphate and urate are shown in Figs 2 to 6 and
forest plots for all other risk factors are shown in Figures A to N in S1 File. Within the tradi-
tional risk factors, male gender, increasing age, smoking, established CV disease, diabetes mel-
litus and increasing total cholesterol were all associated with statistically significant increased
risk of a CV event. Systolic and diastolic blood pressures were not associated with increased
CV event risk.
In the meta-analysis, non-traditional risk factors associated with increased risk of CV
events were albumin (pooled HR 0.62 per g/dL increase, 95% CI 0.52–0.75, p<0.001), haemo-
globin (pooled HR 0.90 per g/dL increase, 95% CI 0.86–0.95, p<0.001), phosphate (pooled HR
1.20 per mg/dL increase, 95% CI 1.08–1.33, p = 0.005) and urate (pooled HR 1.07 per mg/dL
increase, 95% CI 1.02–1.12, p = 0.004). Left ventricular hypertrophy on echocardiogram
(pooled HR 1.78, 95% CI 1.35–2.35, p<0.001) was also found to be associated with an
increased risk of a CV event. Serum urea nitrogen, sodium and pulmonary hypertension on
echocardiogram were all statistically significant but only present in one study each. Calcium,
bicarbonate and parathyroid hormone were not associated with altered risk in the single stud-
ies in which they were included.
Heterogeneity varied substantially between variables (Table 3). Of the potential novel risk
factors for incorporation in to prognostic models albumin (I2 = 66.4%), urate (I2 = 78.3%) and
left ventricular hypertrophy (I2 = 72.1%) showed substantial levels of heterogeneity. Based on
our pre-specified protocol, subgroup analyses to explore heterogeneity were considered for
eGFR and proteinuria stages. These sub-analyses, and other post hoc analyses based on core
cohort characteristics in Table 1, did not explain the heterogeneity for albumin. For urate and
Cardiovascular disease risk factors and CKD
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left ventricular hypertrophy, exploration of heterogeneity was limited by the inclusion of only
two studies in the systematic review.
Discussion
Whilst CV prognostic models are well established for the general population [6,7] it is
unclear how well these models perform in patients with CKD [10]. CV prognostic models
developed specifically for those with CKD exist but have poor methodology and limited clin-
ical applicability [10]. The current systematic review, using a pre-defined and registered pro-
tocol [13], presents the association between routinely collected risk factors and CV disease
events in individuals with CKD. The results confirm that most traditional atherosclerotic
related risk factors confer risk in CKD populations. These include age, gender, smoking,
established CV disease and diabetes mellitus, all of which were statistically significant risk
factors that are incorporated in general population prognostic models and/or are established
risk factors.
Studies of non-traditional risk factors associated with uremia-related arteriosclerosis and
cardiomyopathy were also identified by the systematic review. Of these risk factors, albumin,
haemoglobin and phosphate were included in at least four studies and had a statistically
Table 2. Summary of inclusion of established CV risk factors in multi-variate models included in systematic review.
Study Name Age Gender Ethnicity DM HTN CVD Lipids BMI Smoking eGFR Proteinuria Total
AASK[25] ● ● N/A N/A N/A ● ● ● 5
Ankara[26] ● ● ● ● ● ● 6
CARE FOR HOMe[19] ● ● N/A ● ● ● ● 6
CanPREDDICT[27] ● ● ● ● ● 5
CREATE[39] ● ● ● ● ● 5
CRIC[29] ● ● ● ● ● ●^ ● ● ● ● ● 11
CRISIS[30] ● ● N/A ● ● ● ● ● 6
Digitalis[31] ● ● ● ● ● N/A ● 6
Fujita[32] ● ● ● ● ● ● 6
Genoa[33] ● ● N/A ● ● ● ● ● ● 8
ICKD[20] ● ● ● ● ● ● ● ● ● ● 10
Kaohsiung[34] ● ● ● ● 4
Kyushu[21] ● N/A ● ● ● ● 5
Leuven[22] ● ● N/A ● ● ● ● 6
Madrid[23] ● N/A ● ● ● 4
MAURO[24] ● ● N/A ● ● ● ● ● ● ● 9
Naples[35] ● ● N/A ● ● ● ● ● ● 8
OSERCE-2[36] ● N/A ● ● ● ● ● ● 7
Pravastatin[37] ● N/A ● ● ● ● ● 6
RRI[38] ● ● ● ● ● ● ● ● ● ● ● 11
TREAT[39] ● ● ● N/A ● ● 5
Total 95.2% 71.4% 40.0% 89.5% 80.0% 85.0% 38.1% 33.3% 38.1% 81.0% 52.4%
‘Lipids’ includes correction for using any measure of serum lipids and/or use of lipid lowering medications. N/A indicates that the model could not include the variable
because 100% of study individuals were in this category, for example AASK-RCT was a study of 100% African Americans with hypertension. Where this occurred the
variable was not included for percentage calculations.
corrected for serum creatinine.
https://doi.org/10.1371/journal.pone.0192895.t002
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Table 3. Results for routinely collected risk factors for combined CV events.
Variable Units (continuous)/
Comparator (categorical)
Number of
Studies
Pooled
HR
95% Confidence
Interval
p-value
for HR
I2
(%)
Male female 9 1.451 1.220–1.726 <0.001 0.0
Age per year 12 1.031 1.025–1.038 <0.001 58.6
Smoker non-smoker 5 1.433 1.149–1.787 0.001 3.3
Body mass index per kg/m2 3 0.994 0.964–1.025 0.7 23.0
Cardiovascular
disease
no previous cardiovascular
disease event
11 2.391 2.061–2.773 <0.001 68.1
Ischemic heart
disease
no previous ischemic heart
disease event
5 2.406 1.870–3.096 <0.001 43.2
Congestive heart
failure
no diagnosis of congestive
heart failure
3 1.325 0.989–1.774 0.06 0.0-
Peripheral vascular
disease
no diagnosis of peripheral
vascular disease
1 2.49 1.10–5.63 0.03 -
Diabetes mellitus no diabetes mellitus 14 1.454 1.338–1.579 <0.001 73.5
Systolic blood
pressure
per mmHg 8 1.002 0.999–1.004 0.17 77.8
Diastolic blood
pressure
per mmHg 3 0.999 0.993–1.005 0.67 0.0
Mean arterial
pressure
per 10 mmHg 1 1.14 1.03–1.27 0.01 -
Pulse pressure per mmHg 3 1.002 0.998–1.005 0.38 58.7
Left ventricular
hypertrophy
no left ventricular
hypertrophy on
echocardiogram
2 1.78 1.354–2.351 <0.001 72.1-
Pulmonary
hypertension
no pulmonary hypertension
on echocardiogram
1 1.23 1.00–1.52 0.04 -
Albumin per g/dL 7 0.624 0.519–0.749 <0.001 66.4
Bicarbonate per mEq/L 1 0.99 0.95–1.03 0.6 -
Cholesterol to HDL
ratio
ratio 1 1.03 0.998–1.065 0.07 -
Calcium per mg/dL 1 0.846 0.503–1.422 0.5 -
Hemoglobin per g/dL 8 0.901 0.856–0.948 <0.001 0.0
HDL Cholesterol per mg/dL 1 0.998 0.992–1.003 0.5 -
LDL Cholesterol per mg/dL 2 1.001 0.999–1.003 0.2 0.0
Non-HDL
Cholesterol
per mg/dL 2 1.001 1.000–1.003 0.04 70.4
Parathyroid
hormone
per pg/mL 1 1.00 0.99–1.00 1.00 -
Phosphate per mg/dL 7 1.198 1.084–1.325 <0.001 0.0
Sodium per mmol/L 1 0.954 0.919–0.990 0.01 -
Total cholesterol per mg/dL 3 1.001 1.000–1.002 0.01 65.8
Urate per mg/dL 2 1.068 1.021–1.117 0.004 78.3
Urea nitrogen per 5mg/dL 1 1.14 1.02–1.29 0.03 -
Abbreviations: HDL—high density lipoprotein, HR—hazard ratio, LDL—low density lipoprotein.
Results are given to 3 decimal places, unless data were only available from a single study that published results to 2
decimal places.
https://doi.org/10.1371/journal.pone.0192895.t003
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significant pooled hazard ratio for CV events. Other non-traditional risk factors that could be
candidate risk factors for inclusion in a CV prognostic model include those associated with
cardiomyopathy, such as left ventricular hypertrophy, urate, and those associated with both
cardiomyopathy and arteriosclerosis including calcium, parathyroid hormone and urea nitro-
gen. Some of these risk factors have been considered in prognostic models identified by the
previous systematic review of Tangri et al [10]. McMurray et al demonstrated an association of
CV outcomes with serum albumin but not urea nitrogen [40].
The results of some risk factors were more difficult to interpret. Systolic and diastolic blood
pressures were not statistically significant in their association with CV events. However, mean
arterial pressure was in the single study in which it was considered. Previous studies, including
individual participant meta-analysis, have suggested that the relationship of blood pressure
with mortality and CV events in CKD is non-linear and may be due to uremic related myocar-
dial and vascular remodelling [41–43]. The limited availability of study-level data, and there-
fore the opportunity to study non-linear relationships of blood pressure to CV events in CKD,
makes it difficult to draw a firm conclusion. The ‘Blood Pressure Lowering Treatment Trialists’
Collaboration’ identified that blood pressure lowering in CKD is probably beneficial but was
Fig 2. Forest plot for cardiovascular events of pooled hazard ratio for albumin per g/dL.
https://doi.org/10.1371/journal.pone.0192895.g002
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unable to identify a clear target [44]. Recent analysis of the SPRINT trial in CKD suggested a
possible reduction of CV events with more intensive systolic blood pressure control of
<120mmHg versus <140mmHg (HR 0.81, 95% CI 0.63 to 1.05) [45]. Similarly, lipid measure-
ments, including total cholesterol and low density lipoprotein cholesterol, did not have a clear
relationship. A previous study of myocardial infarction events has suggested a weaker associa-
tion with low density lipoprotein cholesterol as CKD advances [46]. Similarly, the association
of body mass index with CV events was unclear. We were unable to assess the risk associated
with ethnicity as most studies did not present data that could be utilised in models, often
because ethnicity was completely, or nearly, homogenous.
Heterogeneity between studies limits the interpretation of the results of meta-analyses, par-
ticularly in observational studies [47–49]. Further, poor reporting of individual studies makes
comparison of results difficult [50–51]. The ideal method for selecting and combining studies
is uncertain, but by limiting our analysis to studies with at least some adjustment for tradi-
tional CV risk factors and CKD severity, we aimed to reduce heterogeneity but at the cost
of reduced power, via exclusion of some cohort’s results, of the meta-analysis. This approach
also ensures that the results of the reported risk factors reflect the additional prognostic
Fig 3. Forest plot for cardiovascular events of pooled hazard ratio for hemoglobin per g/dL.
https://doi.org/10.1371/journal.pone.0192895.g003
Cardiovascular disease risk factors and CKD
PLOS ONE | https://doi.org/10.1371/journal.pone.0192895 March 21, 2018 11 / 18
information above already established risk factors. Whilst individual patient data meta-analy-
sis is the ‘gold standard’, the additional data from six studies used in the current study may
have reduced bias.
Despite this conservative approach, heterogeneity was substantial [17] for nine risk factors.
Two characteristics of the cohorts and their analysis may explain this. Firstly, the difference in
variable standardisation between studies’ models may contribute to heterogeneity. Secondly,
cohorts varied in the typical stage of CKD, measured through both eGFR and proteinuria, rep-
resented and this may have further increased heterogeneity.
Further limitations include, the conversion of many prognostic factors from continuous
to categorical variables, leading to a loss of statistical power and comparison difficulties
between studies due to differing thresholds [52–55]. Thirdly, models often presented results
to a limited number, typically two, decimal places. This was particularly an issue when a
continuous variable such as age or blood pressure was presented. The results published
would often be the same for both HR and 95% CI e.g. HR 1.01 (95% CI 1.00 to 1.01), thus
when meta-analysed the calculation of the standard error was likely to be inaccurate. We
avoided changing reported HR units where possible to reduce any further inaccuracies
introduced through rounding. Finally, data for eleven risk factors were only included in one
study each, of which four had statistically significant association with CV disease events.
Fig 4. Forest plot for cardiovascular events of pooled hazard ratio for left ventricular hypertrophy.
https://doi.org/10.1371/journal.pone.0192895.g004
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Therefore, replication of these findings for peripheral vascular disease, pulmonary hyper-
tension, mean arterial pressure and serum urea nitrogen in other CKD populations is
required.
The relatively small number of studies identified by the systematic review reflects its specific
pre-specified inclusion criteria. This specificity relates to the outcome inclusion criteria of
composite cardiovascular events including CV specific mortality but excluding all-cause mor-
tality and renal related events. Prominent CKD related studies were identified by the literature
review but excluded based on the inclusion criteria and/or the nature of the risk factors pre-
sented (Table D in S1 File).
Full guidance on presenting risk factor models has been published by the PROGRESS con-
sortium [56]. We would therefore recommend for future studies of CV risk factors in CKD,
models should aim to provide a rationale for the variables used for model adjustment and
avoid categorisation of continuous variables.
Based on the findings of this systematic review, at a minimum, the development of CKD
CV prognostic models should assess traditional and non-traditional CV risk factors including
left ventricular hypertrophy, serum albumin, hemoglobin, phosphate, and urate.
Fig 5. Forest plot for cardiovascular events of pooled hazard ratio for phosphate per mg/dL.
https://doi.org/10.1371/journal.pone.0192895.g005
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